ReviewJournal of cellular and molecular medicine2009
Targeting histone deacetylases for the treatment of disease.
Review in Journal of cellular and molecular medicine, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 46 citations in OpenAlex.
- Dual PROTACs Versus Dual Inhibitors in Oncology: A Medicinal Chemistry and Linker Design Perspective.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Repurposing metformin as a dual-function agent to combat E. coli-induced mastitis: Mechanistic insights into biofilm dispersion and AMPK/SIRT1-mediated NF-κB inhibition.PLoS pathogens · 2026Article
- Bioinformatics and system biology approach to identify the influences of SARS-CoV-2 infections to idiopathic pulmonary fibrosis and chronic obstructive pulmonary disease patients.Briefings in bioinformatics · 2021Article
- Histone deacetylases in vascular permeability and remodeling associated with acute lung injury.Vessel plus · 2018Article
- Fingerprinting of neurotoxic compounds using a mouse embryonic stem cell dual luminescence reporter assay.Archives of toxicology · 2017Article
- Histone acetyltransferase inhibitor CPTH6 preferentially targets lung cancer stem-like cells.Oncotarget · 2016Article
- Mechanisms and clinical significance of histone deacetylase inhibitors: epigenetic glioblastoma therapy.Anticancer research · 2015Review
- Histone deacetylase 6 activity is critical for the metastasis of Burkitt's lymphoma cells.Cancer cell international · 2014Article
- Chromatin remodeling: a new landscape to treat harmful alcohol-use disorders.Future medicinal chemistry · 2013Article
- Silencing histone deacetylase-specific isoforms enhances expression of pluripotency genes in bovine fibroblasts.Cellular reprogramming · 2013Article
- Article
- Chromatin remodeling--a novel strategy to control excessive alcohol drinking.Translational psychiatry · 2013Article
- Differential mRNA expression levels of human histone-modifying enzymes in normal karyotype B cell pediatric acute lymphoblastic leukemia.International journal of molecular sciences · 2013Article
- Gut indigenous microbiota and epigenetics.Microbial ecology in health and disease · 2012Article
- Targeting Huntington's disease through histone deacetylases.Clinical epigenetics · 2011Article
- The redox basis of epigenetic modifications: from mechanisms to functional consequences.Antioxidants & redox signaling · 2011Review
- Article
- Article
- Lessons Learnt from Post-Infectious IBS.Frontiers in physiology · 2011Article
- HDAC inhibitors and neurodegeneration: at the edge between protection and damage.Pharmacological research · 2010Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The 'histone code' is a well-established hypothesis describing the idea that specific patterns of post-translational modifications to histones act like a molecular 'code' recognized and used by non-histone proteins to regulate specific chromatin functions. One modification, which has received significant attention, is that of histone acetylation. The enzymes that regulate this modification are described as lysine acetyltransferases or KATs, and histone deacetylases or HDACs. Due to their conserved catalytic domain HDACs have been actively targeted as a therapeutic target. The pro-inflammatory environment is increasingly being recognized as a critical element for both degenerative diseases and cancer. The present review will discuss the current knowledge surrounding the clinical potential and current development of histone deacetylases for the treatment of diseases for which a pro-inflammatory environment plays important roles, and the molecular mechanisms by which such inhibitors may play important functions in modulating the pro-inflammatory environment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.